Health Policy Stakes in November Midterms — SkimNews
Get the Health newsletter
Daily health & science — research, biotech, public health, the studies worth knowing. Free.
- November's midterm elections are expected to shake up federal health policy debates, with STAT identifying Medicaid funding and drug pricing — alongside research funding — as the key issues at stake.
- A shift would be especially impactful if Democrats seize control of a chamber of Congress, though STAT notes any major policymaking would still require President Trump's signature.
- STAT's reporting draws on interviews with nearly a dozen health industry leaders and lobbyists to outline the most consequential questions facing federal health policy after the midterms.
- The post-midterm outcome will have wide-ranging impacts for America's health system, science, and patients, according to STAT's reporting.
Why it matters: With the health industry already adjusting to Trump's Washington, a midterm-driven shift in Congress could redirect fights over Medicaid, drug pricing, and research dollars — but any legislation still needs Trump's signature, meaning divided-government outcomes matter more than raw partisan wins.
Ask SkimNews
